Old Web
English
Sign In
Acemap
>
authorDetail
>
David Jon Tamura
David Jon Tamura
Pathology
Sipuleucel-T
Atezolizumab
Oncology
Castrate-resistant prostate cancer
2
Papers
4
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (2)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Assessing different sequencing regimens of atezolizumab (atezo) and sipuleucel-T (sipT) in patients who have asymptomatic or minimally symptomatic metastatic castrate-resistant prostate cancer.
2020
Journal of Clinical Oncology
Tanya B. Dorff
Jared David Acoba
Sumanta K. Pal
Mark C. Scholz
David Jon Tamura
Jeffrey Huang
Charles J. Rosser
Show All
Source
Cite
Save
Citations (0)
Phase Ib study assessing different sequencing regimens of atezolizumab (anti-PD-L1) and sipuleucel-T (SipT)in patients who have asymptomatic or minimally symptomatic metastatic castrate resistant prostate cancer.
2020
Journal of Clinical Oncology
Charles J. Rosser
Yosuke Hirasawa
Jared David Acoba
David Jon Tamura
Sumanta K. Pal
Jeffrey Huang
Mark C. Scholz
Tanya B. Dorff
Show All
Source
Cite
Save
Citations (4)
1